Immunological and Virological Responses to Highly Active Antiretroviral Therapy in HIV-1 Infected Children

  • Ravinder Singh
  • Aparna Mukherjee
  • Mohit Singla
  • Bimal Kumar Das
  • Sushil Kumar Kabra
  • Rakesh Lodha
Original Article

Abstract

Objective

To evaluate immunological and virological outcomes in human immunodeficiency virus (HIV) infected children at six months of highly active antiretroviral therapy (HAART).

Methods

Records of HIV infected children <15-y-old were reviewed to identify those who were initiated highly active antiretroviral therapy between 2010 and 2014 and had CD4+ T cell percentage and HIV-1 viral load report at baseline visit and after 6 mo of initiation of the treatment.

Results

Seventy-four HIV infected children [26% girls, median age IQR 36 (24–108) mo] were included in the study. At the end of six months of HAART, median increase of 11% (6–15%) in CD4+ T cell percentage from the baseline levels was observed; nineteen (26%) children showed an increase in CD4+ T cell percentage of 15% or more at 6 mo. Viral load was undetectable (<47 copies/ml) in 27 (36.4%) children; 21 (28.3%) children had 47- < 500 copies/ml; 16 (21.6%) children had 500- < 10,000 copies/ml and 10 (13.5%) children had ≥10,000 copies/ml. At six months, only 15 (20.2%) children exhibited positive immuno-virological response to HAART (≥ 15% increase in CD4% and <47 HIV-1 RNA copies/ml).

Conclusions

While HAART was effective in improving the immunological and virological parameters in the index cohort of children, virological responses were less robust.

Keywords

Pediatric HIV HAART Immunological response Virological response 

References

  1. 1.
    UNAIDS. Report on the Global AIDS Epidemic. Avaialble at: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/. UNAIDS Global Report 2013 en. pdf. Accessed on 27th May 2016.
  2. 2.
    Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet. 2010;376:49–62.CrossRefPubMedGoogle Scholar
  3. 3.
    Fassinou P, Elenga N, Rouet F, et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan. Cote d'Ivoire AIDS. 2004;18:1905–13.CrossRefPubMedGoogle Scholar
  4. 4.
    Janssens B, Raleigh B, Soeung S, et al. Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. Pediatrics. 2007;120:e1134–40.CrossRefPubMedGoogle Scholar
  5. 5.
    Song R, Jelagat J, Dzombo D, et al. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya. Pediatrics. 2007;120:e856–61.CrossRefPubMedGoogle Scholar
  6. 6.
    NACO. National AIDS control organization: guidelines for HIV care and treatment in infants and children. Ministry of Health and Family Welfare, Govt of India: New Delhi; 2006.Google Scholar
  7. 7.
    Kassa D, Gebremichael G, Alemayehu Y, Wolday D, Messele T, van Baarle D. Virologic and immunologic outcome of HAART in human immunodeficiency virus (HIV)-1 infected patients with and without tuberculosis (TB) and latent TB infection (LTBI) in Addis Ababa, Ethiopia. AIDS Res Ther. 2013;10:18.Google Scholar
  8. 8.
    Nyesigire Ruhinda E, Bajunirwe F, Kiwanuka J. Anaemia in HIV-infected children: severity, types and effect on response to HAART. BMC Pediatr. 2012;12:170.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kokeb M, Degu G. Immunological response of HIV-infected children to highly active antiretoviral therapy at Gondar university hospital, north-western Ethiopia. Ethiop J Health Sci. 2016;26:25–30.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Wamalwa DC, Farquhar C, Obimbo EM, et al. Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children. J Acquir Immune Defic Syndr. 2007;45:311–7.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Reddi A, Leeper SC, Grobler AC, et al. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatr. 2007;7:13.Google Scholar
  12. 12.
    Sophan S, Meng CY, Pean P, et al. Virologic and immunologic outcomes in HIV-infected Cambodian children after 18 months of highly active antiretroviral therapy (HAART). Southeast Asian J Trop Med Public Health. 2010;41:126–37.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Rutstein RM, Gebo KA, Flynn PM, et al. Immunologic function and virologic suppression among children with perinatally acquired HIV infection on highly active antiretroviral therapy. Med Care. 2005;43:III15–22.PubMedGoogle Scholar
  14. 14.
    Walker AS, Doerholt K, Sharland M, Gibb DM, Collaborative HIVPSSC. Response to highly active antiretroviral therapy varies with age: the UK and Ireland collaborative HIV Paediatric study. AIDS. 2004;18:1915–24.CrossRefPubMedGoogle Scholar
  15. 15.
    Mutwa PR, Boer KR, Asiimwe-Kateera B, et al. Safety and effectiveness of combination antiretroviral therapy during the first year of treatment in HIV-1 infected Rwandan children: a prospective study. PLoS One. 2014;9:e111948.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Franco JM, Leon-Leal JA, Leal M, et al. CD4+ and CD8+ T lymphocyte regeneration after anti-retroviral therapy in HIV-1-infected children and adult patients. Clin Exp Immunol. 2000;119:493–8.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2017

Authors and Affiliations

  • Ravinder Singh
    • 1
  • Aparna Mukherjee
    • 1
  • Mohit Singla
    • 1
  • Bimal Kumar Das
    • 2
  • Sushil Kumar Kabra
    • 1
  • Rakesh Lodha
    • 1
  1. 1.Department of PediatricsAll India Institute of Medical SciencesNew DelhiIndia
  2. 2.Department of MicrobiologyAll India Institute of Medical SciencesNew DelhiIndia

Personalised recommendations